Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis

医学 多西紫杉醇 前列腺癌 荟萃分析 肿瘤科 雄激素剥夺疗法 内科学 随机对照试验 恩扎鲁胺 癌症 雄激素受体
作者
Soumyajit Roy,Gagan Fervaha,Daniel E. Spratt,Yilun Sun,Amar U. Kishan,Andrew Loblaw,Shawn Malone,Michael Ong,Fred Saad,Christopher J.D. Wallis,Scott C. Morgan
出处
期刊:European Urology [Elsevier BV]
卷期号:86 (1): 10-17 被引量:8
标识
DOI:10.1016/j.eururo.2024.03.018
摘要

The utility of prostate radiotherapy (RT) is unclear in men with metastatic hormone-sensitive prostate cancer (mHSPC) receiving intensified systemic therapy with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs). We performed a network meta-analysis of randomized controlled trials (RCTs) to investigate the role of prostate RT in low-volume mHSPC. Bibliographic databases and conference proceedings were searched through July 2023 for RCTs evaluating the addition of ARPIs or prostate RT to standard of care (SOC) systemic therapy, defined as ADT or ADT plus docetaxel, for the initial treatment of mHSPC. We focused exclusively on aggregate data from the low-volume mHSPC subpopulation in these trials. We pooled the treatment arms into four groups: SOC, SOC plus ARPI, SOC plus RT, and SOC plus ARPI plus RT. The primary outcome was overall survival (OS). To compare treatment strategies, a fixed-effects Bayesian network meta-analysis was undertaken, while a Bayesian network meta-regression was performed to account for across-trial differences in docetaxel use as part of SOC and in proportions of patients with de novo presentation. Ten RCTs comprising 4423 patients were eligible. The Surface Under the Cumulative Ranking Curve scores were 0.0006, 0.45, 0.62, and 0.94 for SOC, SOC plus RT, SOC plus ARPI, and SOC plus ARPI plus RT, respectively. On a meta-regression, in a population with de novo mHSPC and no docetaxel use, we did not find sufficient evidence of a difference in OS between SOC plus ARPI plus RT versus SOC plus ARPI (hazard ratio [HR]: 0.76; 95% credible interval: 0.51–1.16) and SOC plus RT versus SOC plus ARPI (HR: 1.10; 95% credible interval: 0.92–1.42). There was some evidence that SOC plus ARPI plus RT reduced mortality compared with the next best strategy of SOC plus ARPI in patients with low-volume de novo mHSPC. A meta-analysis with individual patient data or an RCT is needed to confirm these findings.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zriverm发布了新的文献求助10
刚刚
量子星尘发布了新的文献求助10
刚刚
希望天下0贩的0应助方格采纳,获得10
1秒前
leslie驳回了归尘应助
2秒前
Wl发布了新的文献求助10
3秒前
Lucas应助何1采纳,获得10
4秒前
小仙女212发布了新的文献求助10
5秒前
6秒前
c_123发布了新的文献求助10
6秒前
6秒前
Lorain完成签到,获得积分10
7秒前
8秒前
8秒前
9秒前
耍酷问兰发布了新的文献求助10
11秒前
11秒前
Wl关注了科研通微信公众号
11秒前
11秒前
周声声发布了新的文献求助10
13秒前
孙亦沈发布了新的文献求助10
13秒前
Lucas应助肖肖采纳,获得10
14秒前
Liufgui应助MTRQ采纳,获得10
15秒前
15秒前
南瓜气气发布了新的文献求助30
16秒前
18秒前
19秒前
钮卿发布了新的文献求助10
19秒前
YJ888发布了新的文献求助10
20秒前
欣喜沛芹发布了新的文献求助10
21秒前
21秒前
静默完成签到 ,获得积分10
21秒前
22秒前
华仔应助大罗采纳,获得10
22秒前
wonhui发布了新的文献求助10
22秒前
相信未来完成签到,获得积分0
22秒前
天天快乐应助科研通管家采纳,获得10
23秒前
大个应助科研通管家采纳,获得10
24秒前
24秒前
24秒前
科研通AI2S应助科研通管家采纳,获得10
24秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989069
求助须知:如何正确求助?哪些是违规求助? 3531351
关于积分的说明 11253589
捐赠科研通 3269939
什么是DOI,文献DOI怎么找? 1804851
邀请新用户注册赠送积分活动 882074
科研通“疑难数据库(出版商)”最低求助积分说明 809073